GSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...

Additionally, the company has developed next-generation drugs in respiratory and HIV areas that should help mitigate both branded and generic competition. We expect GSK to be a major competitor in ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will ...

GSK reported a mixed third-quarter performance on Wednesday, with a notable boost from specialty medicines helping to offset ...

GSK GSK-1.51%decrease; red down pointing triangle cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations in the third quarter due ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year, citing lower-than-expected demand. The company said it’s now expecting a low single-digit fall in vaccine sales this ...

GSK said that despite the fall in sales, Arexvy still had about a two-thirds share of the retail market, where most of the ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: Related Stocks Indices ...

GSK is delivering consistent financial performance ... particularly in oncology and HIV. We expect this momentum to continue with growth from these assets and several material launch opportunities ...